A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-08-26
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-17 (study day 3); relationship: not assessed
mild
assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-17 (study day 3); relationship: Y
mild
assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-09-17 (study day 3); relationship: Y
Data queries
No data queries.